Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Asco 2021 movers – PDS wins, but big pharma reigns
PDS and Spectrum rise, while Black Diamond, Alpine, Harpoon and Macrogenics disappoint, and others ride on big pharma’s coattails.
Asco 2020 movers – cell therapy companies dominate the risers
Adaptimmune and Allogene led numerous cell therapy companies higher over the Asco period, while Cytomx and Arvinas suffered the biggest losses.
Novartis cast-off gives Pharming a gap-filler
Pharming picks up Novartis’s late-stage PI3K inhibitor and plans to launch it for an ultra-rare disease. How will the competition respond?
